10-K: Scholar Rock Faces FDA Delay for SMA Drug, Secures $350M Financing

Scholar Rock's lead SMA drug, apitegromab, faces regulatory delays due to third-party manufacturing issues, while the company secures new financing and advances its pipeline.

Summary

• Scholar Rock Holding Corporation is a global biopharmaceutical company focused on rare, severe, and debilitating neuromuscular diseases, particularly Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD).
• The company's lead product candidate, apitegromab, is an investigational monoclonal antibody designed to inhibit myostatin activation to increase muscle mass and strength.
• A Biologics License Application (BLA) for apitegromab in SMA was submitted to the FDA in January 2025 and granted Priority Review in March 2025; a Marketing Authorisation Application (MAA) was accepted by the EMA in March 2025.
• On September 22, 2025, the FDA issued a Complete Response Letter (CRL) for apitegromab's BLA, citing cGMP deficiencies at a third-party fill-finish facility, which has delayed potential U.S. commercialization.
• The CRL observations were site-related and not specific to apitegromab's efficacy or safety data, or the third-party drug substance manufacturer.
• A constructive Type A meeting with the FDA was completed in November 2025, and the third-party facility received a warning letter in November 2025, with ongoing efforts to resolve the issues.
• Positive top-line data from the Phase 3 SAPPHIRE study for apitegromab in children and adults with SMA were reported in October 2024, demonstrating a statistically significant and clinically meaningful improvement in motor function (HFMSE mean difference of 1.8 points for combined 10/20 mg/kg doses vs. placebo, p=0.0192).
• The company initiated the Phase 2 OPAL study for apitegromab in infants and toddlers with SMA and plans to initiate a Phase 2 FORGE study for FSHD in mid-2026.
• A Phase 1 study of subcutaneous apitegromab was completed, showing favorable bioavailability and a comparable pharmacodynamic profile.
• A Phase 1 study of SRK-439, a novel subcutaneously administered anti-myostatin antibody, is underway with topline data anticipated in the second half of 2026.
• The Phase 2 EMBRAZE study demonstrated proof-of-concept for apitegromab to preserve lean mass during tirzepatide-induced weight loss.
• The company reported a net loss of $377.9 million for the year ended December 31, 2025, an increase from $246.3 million in 2024, with an accumulated deficit of $1.3 billion.
• Research and development expenses increased by 12.9% to $208.4 million in 2025, while general and administrative expenses surged by 161.0% to $176.2 million, driven by commercialization build-out and leadership changes.
• Cash, cash equivalents, and marketable securities decreased to $367.6 million as of December 31, 2025, from $437.3 million in 2024.
• In February 2026, the company secured a new Financing Agreement with Blue Owl Capital Corporation for up to $350.0 million, using an initial $100.0 million to repay previous debt of $103.7 million to Oxford Finance LLC.
• Existing liquidity is expected to fund operating expenses and capital expenditure requirements into 2027, but additional capital will be required to complete clinical development and commercialization for all current programs.
• The company no longer qualifies as a smaller reporting company as of January 1, 2026, which will lead to increased compliance costs and demands on management.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with mixed sentiment. While significant clinical progress and new financing are positive, the FDA's CRL and associated manufacturing issues for the lead product candidate, apitegromab, represent a material setback and introduce considerable uncertainty and delay to commercialization plans. The increased net loss and G&A expenses also reflect a challenging financial environment.

Positives

• Positive Phase 3 SAPPHIRE study data for apitegromab in SMA, achieving primary endpoint with statistically significant and clinically meaningful improvement in motor function (HFMSE mean difference of 1.8 points, p=0.0192).
• Apitegromab received Priority Review designation from the FDA and validation of MAA from the EMA for SMA, indicating regulatory recognition of its potential.
• FDA granted Fast Track, Rare Pediatric Disease, and Orphan Drug designations for apitegromab in SMA, potentially expediting development and providing market exclusivity benefits.
• EMA granted PRIME designation and EC granted orphan medicinal product designation for apitegromab in SMA, offering enhanced support and potential for accelerated assessment.
• Successful completion of Phase 1 study for subcutaneous apitegromab, demonstrating favorable bioavailability and a comparable pharmacodynamic profile, offering a more convenient administration option.
• Initiation of Phase 2 OPAL study for apitegromab in infants and toddlers with SMA and planned Phase 2 FORGE study for FSHD, expanding potential indications and market opportunities.
• Completion of Phase 2 EMBRAZE study, demonstrating proof-of-concept for apitegromab to drive statistically significant preservation of lean mass during tirzepatide-induced weight loss, suggesting broader therapeutic potential.
• Strengthened leadership team with key appointments, positioning the company for transition toward a global commercial-stage organization.
• Secured new financing of up to $350.0 million with Blue Owl, providing significant capital for future operations and repaying previous debt.
• Advancing activities at a second US-based fill-finish facility to strengthen supply continuity and support future commercial demand of apitegromab.

Negatives

• Received a Complete Response Letter (CRL) from the FDA on September 22, 2025, for apitegromab's BLA due to cGMP deficiencies at a third-party fill-finish facility, delaying potential U.S. commercialization.
• The third-party fill-finish facility received a warning letter from the FDA in November 2025, indicating ongoing regulatory issues that must be resolved.
• Net loss increased to $377.9 million in 2025 from $246.3 million in 2024, and the accumulated deficit reached $1.3 billion, reflecting substantial operating losses.
• General and administrative expenses increased significantly by 161.0% to $176.2 million in 2025, primarily driven by commercialization build-out and leadership changes, contributing to higher cash burn.
• Ongoing opposition proceedings for four granted European patents, with two patents (EP2981822, EP3368069B1) revoked by opposition divisions, subject to appeal, introducing intellectual property uncertainty.
• Reliance on a limited number of third-party manufacturing and supply partners, including a single source for drug substance and fill-finish, poses supply chain risks.
• The company no longer qualifies as a smaller reporting company as of January 1, 2026, which will increase compliance costs and demands on management.

Risks

• The regulatory approval process for apitegromab in the U.S., EU, and other jurisdictions will be lengthy, time-consuming, and inherently unpredictable, with potential for failure or delays.
• The CRL from the FDA in September 2025 requires BLA resubmission and has delayed progress toward potential commercialization of apitegromab.
• The CRL could impact the EMA's review process for the MAA, potentially leading to delays or resubmission.
• The company has never commercialized a product and is building commercial infrastructure, which may not be successful, negatively impacting commercialization.
• Changes or disruptions at the FDA and other government agencies (e.g., funding cuts, shutdowns) could prevent timely review and approval of regulatory submissions.
• Unfavorable pricing and reimbursement decisions in the EU could significantly delay or limit patient access and materially reduce anticipated revenues.
• Product development is lengthy and expensive, with uncertain outcomes; clinical trials may incur additional costs, delays, or fail to meet endpoints.
• Results of preclinical studies and early-stage clinical trials may not be predictive of future results in later-stage trials or different indications.
• Reliance on third parties to conduct clinical trials and preclinical studies poses risks if they fail to meet contractual duties, deadlines, or regulatory requirements.
• Preclinical development is uncertain, and programs may never advance to clinical trials.
• Reliance on a limited number of third-party manufacturing and supply partners creates risks of supply limitations, interruptions, or quality issues.
• Reliance on third-party logistics, distributors, pharmacies, and patient service providers may lead to distribution disruptions, capacity constraints, or patient access gaps.
• Economic uncertainty, geopolitical instability, inflation, and interest rates could adversely affect business, including supply chains.
• Difficulty in managing organizational growth, including hiring and retaining skilled personnel, could impair development and commercialization.
• Loss of key executives or highly skilled personnel could disrupt strategy and operational execution.
• Internal computer systems or those of third parties may fail or suffer security breaches, leading to data loss, delays, or liability.
• Employees, contractors, or partners may engage in misconduct, leading to non-compliance with regulatory standards and increased liability.
• Ongoing healthcare legislative and regulatory reform measures could adversely affect business, including pricing, reimbursement, and patient assistance programs.
• Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact product revenues.
• Relationships with healthcare providers and payors are subject to anti-kickback, fraud, and abuse laws, potentially leading to sanctions.
• Failure to comply with health care privacy and data protection laws could lead to enforcement actions, litigation, and adverse publicity.
• Artificial intelligence presents risks, including security risks to confidential information, intellectual property infringement, and increasing regulatory burdens.
• Failure to comply with environmental, health, and safety laws could result in fines or penalties.
• Product liability lawsuits could lead to substantial liabilities and limit commercialization.
• Concentration of laboratory operations in one location poses risks from business interruptions or natural disasters.
• Inadequate patent protection or challenges to existing patents could diminish the value of intellectual property and competitive advantage.
• Inability to protect trade secrets could harm business and competitive position.
• Third parties may assert intellectual property infringement claims, leading to litigation and delays.
• Changes in patent law could diminish the value of patents.
• Reliance on intellectual property licensed from third parties; failure to comply with license obligations could result in loss of significant rights.
• Inability to obtain necessary rights for future product candidates on acceptable terms.
• The price of common stock is volatile, and stockholders could lose all or part of their investment.
• The company's ability to use net operating loss carryforwards and tax credit carryforwards may be limited.
• Adverse developments in the financial services industry could affect business operations and financial condition.
• Potential losses on securities held in the investment portfolio if interest rates increase or economic conditions deteriorate.
• Restrictions on operating and financial flexibility due to loan agreements.
• Anti-takeover provisions could delay or prevent a change of control.
• Inaccurate or unfavorable research by securities analysts could cause stock price decline.
• Securities litigation is expensive and could divert management attention.
• Exclusive forum provisions in bylaws could limit stockholders' ability to obtain a favorable judicial forum.
• Substantial number of warrants and equity awards could result in dilution.

Future Outlook

The company anticipates 2026 could be a transformational year with the potential to become a commercial-stage biotech company, assuming regulatory approvals for apitegromab in SMA. Plans include commercial launches in the U.S. and Europe (starting with Germany), expanding apitegromab's impact to infants and toddlers with SMA and to FSHD, and advancing the anti-myostatin pipeline with SRK-439. The company expects to continue incurring significant losses and will require additional capital to complete clinical development and commercialization for its programs, with existing resources projected to fund operations into 2027.

Management Comments

• "We believe 2026 could be a transformational year for Scholar Rock as we anticipate the potential to become a commercial-stage biotech company."
• "We plan to resubmit the apitegromab BLA at such time after the facility resolves the cGMP deficiencies identified in the CRL, however, there can be no guarantee of the timing of the facility's resolution of those deficiencies or that the FDA will approve apitegromab upon our resubmission of the BLA."
• "We believe that apitegromab has the potential to be the first muscle-targeted therapy that is aimed at improving motor function in patients with SMA who are receiving an SMN-targeted therapy."
• "We believe the new standard of care will consist of a muscle-targeted therapy, complemented by an SMN-targeted therapy in order to drive clinically meaningful impacts for patients."
• "Our mission is to discover, develop, and deliver novel, life-transforming therapies to people suffering from rare, severe, and devastating neuromuscular diseases."
• "We expect general and administrative expense to continue to be substantial as we continue to invest in building the infrastructure to support the commercialization of apitegromab."

Industry Context

StockSavvy.ai notes that Scholar Rock operates in the highly competitive biopharmaceutical industry, specifically targeting rare neuromuscular diseases. The company's focus on myostatin inhibition represents a novel approach compared to existing SMN-targeted therapies for SMA, aiming to address unmet needs in muscle function. The successful Phase 3 SAPPHIRE data positions apitegromab as a potential first-in-class muscle-targeted therapy for SMA, which could complement current SMN-targeted treatments from competitors like Roche, Biogen, and Novartis. The expansion into FSHD and the development of SRK-439 indicate a strategy to build a leading anti-myostatin pipeline, differentiating itself through selective growth factor modulation. The positive proof-of-concept in lean mass preservation during GLP-1 induced weight loss also highlights potential broader applications for myostatin inhibition, a growing area of interest in metabolic disorders.

Comparison to Industry Standards

• Apitegromab is the first and only myostatin inhibitor with a positive, statistically significant Phase 3 outcome for SMA, differentiating it from other myostatin-targeting drug development programs that have faced limitations or termination (e.g., a soluble decoy of the ActRIIb receptor in Duchenne Muscular Dystrophy, or anti-ActRII monoclonal antibody in obesity).
• Traditional myostatin inhibitors often inadvertently inhibit GDF11 due to structural similarities; Scholar Rock's approach of targeting latent forms aims for heightened selectivity, potentially limiting off-target effects seen in other programs (e.g., bleeding side effects, suppression of follicle stimulating hormone, muscle spasms, acne, changes in triglyceride levels, and higher discontinuation rates in combination GLP-1 studies).
• The HFMSE improvement of 1.8 points (p=0.0192) in the SAPPHIRE study for apitegromab in SMA is presented as clinically meaningful, positioning it against existing SMN-targeted therapies (nusinersen, risdiplam) which address SMN deficiency but leave unmet needs in muscle function.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Gilead collaboration period expired on December 19, 2021, and the option exercise period was terminated on January 6, 2022.
• Adimab Agreement for antibody discovery and optimization services, with option exercise fees and potential milestone and royalty payments.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises and warrant exercises. Stock price volatility is a risk. The FDA CRL could negatively impact share price. New financing provides liquidity but also debt obligations.
• Patients (SMA): Delay in U.S. approval of apitegromab means delayed access to a potential new muscle-targeted therapy. Positive Phase 3 data offers hope for improved motor function.
• Employees: Leadership team transformation and commercial build-out indicate growth and new opportunities, but also potential for increased demands and competition for talent. Severance costs indicate some personnel changes.
• Third-party Manufacturers: The FDA CRL and warning letter highlight regulatory scrutiny and potential operational challenges for the third-party fill-finish facility, impacting the company's supply chain.
• Regulatory Bodies: Ongoing engagement with FDA and EMA for approvals and resolution of manufacturing issues.

Next Steps

• Resubmit apitegromab BLA to the FDA after the third-party fill-finish facility resolves cGMP deficiencies.
• Continue working with the FDA and the third-party fill-finish facility to resolve outstanding issues cited in the warning letter.
• Initiate Phase 2 FORGE study for apitegromab in FSHD in mid-2026.
• Anticipate topline data from Phase 1 study of SRK-439 in the second half of 2026.
• Continue development activities for subcutaneous apitegromab, including planned FDA and EMA regulatory engagements.
• Continue the ongoing ONYX open-label extension study for apitegromab in SMA.
• Seek partnerships for SRK-181, SRK-373, SRK-256, and for myostatin inhibition in combination with GLP-1 weight loss approaches.
• Build out commercial organization in Europe, starting with Germany, to support planned launch.
• Hire additional managerial, clinical development, scientific, regulatory, commercial, and administrative personnel.
• Comply with additional disclosure and compliance requirements as a non-smaller reporting company starting Q1 2026.
• Potentially draw down additional delayed draw term loans from Blue Owl, subject to conditions.

Key Dates

Recommendation

The company has demonstrated strong clinical data for apitegromab in SMA and is advancing a promising pipeline in rare neuromuscular diseases. The new financing provides a solid liquidity runway into 2027. However, the FDA's Complete Response Letter (CRL) due to manufacturing issues introduces significant regulatory uncertainty and delays the commercial launch of its lead product, which is a major setback. While the issues are not related to the drug's efficacy or safety, the timeline for resolution is unpredictable. Investors should hold to monitor the resolution of the manufacturing issues and the subsequent BLA resubmission, as well as the progress of the broader pipeline.

Keywords

Biopharmaceutical, Spinal Muscular Atrophy, SMA, Facioscapulohumeral Muscular Dystrophy, FSHD, Apitegromab, Myostatin Inhibitor, SRK-439, Rare Neuromuscular Diseases, SEC Filing, 10-K, Clinical Trials, FDA Approval, EMA Approval, Regulatory Delay, cGMP, Biotech, Drug Development, Financial Performance, Capital Raise, Intellectual Property, Corporate Governance